Vertex Pharmaceuticals reports a 42.7% reduction in kidney damage marker in Phase 2b trial of inaxaplin — a first-in-class drug for APOL1-mediated kidney disease, which has no approved treatments. Enrollment in the larger Phase 2/3 trial is now complete. #ScienceUpdate #KidneyDisease
